Study of an investigational drug for primary tauopathies
Part of Brain & nervous system, Eyes & vision, Hormones & metabolism, Mental health clinical trials.
This trial tests an experimental drug called NIO752 in people with certain brain conditions known as primary tauopathies, which include progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and frontotemporal dementia caused by MAPT gene changes. The goal is to see if the drug is safe and how it affects the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 41 and 81 years old.
- You can walk at least 10 steps with minimal help (like using a cane or holding someone's arm).
- Your symptoms started within the last 5 years.
- You have a caregiver or family member who can come to study visits and provide information about you.
- If you take medications for your symptoms, the dose must be stable for at least 8 weeks before the study starts.
- You must have a diagnosis of PSP, CBS, or a MAPT gene mutation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a supplement called nicotinamide riboside (NR) can help people with rare forms of parkinsonism (PSP, MSA, or CBS). It is a double-blind study, meaning neither you nor the doctors will know if you are getting the real supplement or a placebo.
This trial uses a special PET scan to see how a new imaging agent (called 11C-M503) travels through the body and brain. It may help researchers better understand brain conditions like Parkinson's disease.
This study uses brain imaging to look at a protein called tau in people with progressive supranuclear palsy (PSP). It aims to better understand the disease and how tau changes over time, which may help future treatments.
This study tracks changes in people with Parkinson's disease, other movement disorders, or cognitive decline to find better ways to measure disease progression.
This study uses brain imaging and tests to better understand Parkinson's disease and related conditions. It aims to improve diagnosis by comparing scans across different groups of people.
This trial tests a new medicine called NIO752 for people with progressive supranuclear palsy (PSP), a condition that affects movement, balance, and thinking. The goal is to see if it can help slow the disease's progression.
Hear when a new Progressive Supranuclear Palsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.